Capricor Therapeutics (CAPR) Equity Ratio (2010 - 2026)

Capricor Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.85 for Q1 2026.

• In Q1 2026, Equity Ratio rose 2.9% year-over-year to 0.85; the TTM figure through Mar 2026 stood at 0.85 (up 2.9% YoY), while the FY2025 annual figure was 0.86, up 0.68% from the prior year.
• Equity Ratio was 0.85 for Q1 2026 at Capricor Therapeutics, down from 0.86 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q4 2025 to a low of 0.05 in Q3 2023.
• Historically, Equity Ratio has averaged 0.47 across 5 years, with a median of 0.38 in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio tumbled 116.82% in 2023, then soared 1626.31% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.24 in 2022, then surged by 63.56% to 0.38 in 2023, then surged by 121.73% to 0.85 in 2024, then rose by 0.68% to 0.86 in 2025, then dropped by 0.57% to 0.85 in 2026.
• The last three Equity Ratio figures came in at 0.85 (Q1 2026), 0.86 (Q4 2025), and 0.66 (Q3 2025), per Business Quant data.